Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)

CD19 directed chimeric antigen receptor T cell (CART19) therapy has resulted in unprecedented clinical outcomes. However, its success in chronic lymphocytic leukemia (CLL) has been modest to date. An increasing body of evidence indicates that impaired CART cell fitness is the predominant mechanism of the relative dysfunction in CLL. The immunosuppressive microenvironment in CLL is well known and may be related to the abundance of circulating extracellular vesicles (EVs) bearing immunomodulatory properties.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Michelle J. Cox, Fabrice Lucien-Matteoni, Reona Sakemura, Justin C. Boysen, Yohan Kim, Michael J. Hansen, Claudia Manriquez Roman, Erin E. Tapper, Sydney Crotts, Kendall J. Schick, Mehrdad Hefazi, Paulina Horvei, Michael W. Ruff, Sameer A. Parikh, Neil E. Tags: 3 Source Type: research